News

Pegsitacase metabolises poorly soluble uric acid into highly soluble allantoin, thus lowering uric acid levels, and its long half-life may provide for an extended duration of uric acid-lowering

GSK also added that the report picked information from documents, which mischaracterized GlaxoSmithKline’s comprehensive efforts to research Avandia and communicated those findings to regulators, physicians and patients. GSK

Investors in the Series D round included Commonwealth Capital Ventures, FLIR Systems, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures and HLM

The Phase IIb trial is a multi-center, global, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients with a primary endpoint of a reduction in incidence of new

The solution removes a key bottleneck in the current workflow for sequencing by replacing the tedious gel isolation and purification steps used for size selection of sheared genomic

CEL-SCI’s rheumatoid arthritis vaccine CEL-2000 was discovered as part of work with the company’s ongoing research and development activities with its LEAPS (Ligand Epitope Antigen Presentation System) technology.

Watson’s 174mg and 348mg strength bupropion hydrobromide tablet products are generic versions of Biovail’s Aplenzin ER, which is indicated for major depressive disorder. Reportedly, Biovail filed suit against

By employing demand flow technology throughout its manufacturing system, Segue provides a standardised process and methodology that drives consistent change management and improvement with a proven roadmap and

The companies said that the agreement includes an upfront fee and potential milestones totaling over $200m as well as product royalties. Lauren Silverman, managing director of Novartis Option